reports
Troubadour Resources Inc: 1 director
A director at Troubadour Resources Inc sold 1,226,800 shares at 0.050CAD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Trillium Therapeutics Receives Final Court Order Approving Arrangement
Trillium Therapeutics Receives Final Court Order Approving Arrangement CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the “Arrangement”) with PF Argentum ULC (“PF Argentum”), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”). Pur...
Trillium Securityholders Approve Acquisition by Pfizer
Trillium Securityholders Approve Acquisition by Pfizer CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the i...
TRILLIUM THERAPEUTICS sees a downgrade to Negative on account of less ...
The independent financial analyst theScreener just lowered the general evaluation of TRILLIUM THERAPEUTICS (CA), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date October 19, 2021, the closing price was CAD 21.86 and its targe...
Pfizer to Acquire Trillium Therapeutics Inc.
Pfizer to Acquire Trillium Therapeutics Inc. Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives NEW YORK and CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into ...
Trillium Therapeutics Reports Second Quarter 2021 Operating and Financ...
Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. “The second quarter 2021 was an important period for Trillium, during which time we communicated our go-forward stra...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 ...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine. TTI-622...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 ...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and ven...
Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board o...
Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. “We are excited to welcome Dr. Mackey to our board of directors,” said Paolo Pucci, Lead Director of Trillium. “Her significant executive e...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 ...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first patient with TTI-621 (SIRPα-IgG1 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with doxorubicin in a Phase 1b/2 study in leiomyosarcoma (LMS). TTI-621 binds CD47, an inn...
Trillium Therapeutics Joins Russell 2000® and 3000® Indices
Trillium Therapeutics Joins Russell 2000® and 3000® Indices CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell 2000® and 3000® Indices effective after the US market opens on June 28. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place f...
Trillium Announces Voting Results From the Annual General and Special ...
Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 8, 2021. The results of the director elections were as follows: NameVotes inFavor% Votes inFavorVotesWithheld% VotesWithheldMr. Luke Beshar45,690,55189.65,331,29...
Trillium Therapeutics Reports First Quarter 2021 Operating and Financi...
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. “Coming off an R&D Day last week, we are very excited to have launched a new chapter in Trillium’s evolution,” said Jan Skv...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b St...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfi...
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Progr...
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure;TTI-621 monotherapy shows 18-29% ORR in R/R T- and B-cell lymphomas at 0.2-2.0 mg/kg doses, including 3 new responses (1 CR + 2 PRs) in cutaneous T-cell lymphoma (CTCL) since last data disclosure;TTI-62...
Trillium Therapeutics to Host Virtual R&D Day for Investors on April 2...
Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021 CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021. The R&D Day agenda will include: a clinical update for TTI-622 and TTI-621,new strategic priorities in terms of target indications and drug combinations across hematologic m...
Trillium Therapeutics Reports Annual Operating and Financial Results a...
Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day Wide-ranging transformation program completedR&D Day scheduled for April 28, 2021, to provide data updates, and announce strategic priorities and clinical development plan going forward$291.2 million in cash, cash equivalents and marketable securities as of December 31, 2020 CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported fina...
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual M...
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021 CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides guidance for 2021. “Our presentations at ASH, as of a data cutoff of November 3, build upon our last corporate up...
Trillium Therapeutics to Present Clinical Data at the 62nd American So...
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020. TTI-622: Poster Presentation, Publication Number 1191Investigational CD47-Blocker TTI-622 Shows Single-Agent Activ...
Trillium Therapeutics Reports Third Quarter 2020 Financial and Operati...
Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the nine months ended September 30, 2020. “Third quarter was a productive quarter for Trillium,” said Jan Skvarka, the Company’s President and Chief Executive Officer. “We reported encouraging clinical data updates for both TTI-622 a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.